Skip to main content

FoundationOne®液体CDX.

什么是底座®Liquidcdx?

FoundationOne Liquid CDx

底座液体CDX是一种FDA批准的伴随诊断,分析了简单的血液绘制的指导推荐基因。它是唯一的FDA批准的基于血液的测试,用于分析超过300个基因 - 使其成为市场上最全面的FDA批准的液体活组织检查。此次测试报告血肿突变(BTMB),微卫星不稳定性(MSI),这项试验报告血液肿瘤突变(BTMB),和肿瘤级分值。

With more targeted therapy options, comprehensive genomic profiling with FoundationOne Liquid CDx can help guide treatment strategies and help predict patient benefit across multiple cancer indications.

订单测试

Over 300 genes, bTMB, and MSI-H*

包括指南推荐的基因和生物标志物,以帮助指导治疗选择,并确定固体肿瘤患者的临床试验选择。金博宝188亚洲体育app

2 tubes of blood

Requires only two 8.5mL tubes of blood to identify targeted therapy, immunotherapy, and clinical trial options.

迹象

Companion Diagnostic Indications

迹象

检测到生物标志物 FDA-approved Therapy

alk.重新排列

alecensa®(alectinib)

EGFR外显子19删除和EGFRexon 21 L858R substitution

Iressa®(gefitinib),Tagrisso®(Osimertinib),或Tarceva®(erlotinib)

检测到生物标志物 FDA-approved Therapy

BRCA1,BRCA2,ATMalterations

Lynparza®(olaparib)

BRCA1,BRCA2alterations

rubRaca®.(rucaparib)

检测到生物标志物 FDA-APPROVED THERAPY

BRCA1, BRCA2alterations

rubRaca®.(rucaparib)

检测到生物标志物 FDA-APPROVED THERAPY

Pik3ca.mutations C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R; and H1047L, H1047R, and H1047Y

Piqray®(alpelisib)

Real-life Results

Real-life Results

Learn more about the clinical utility of FoundationOne Liquid CDx in a number of cancer types.

  • SAMPLE REPORT

    非小细胞肺癌(NSCLC)Sample Report

    查看底座液体NSCLC样本报告。此报告显示结果EGFRexon 21 L858R substitution detected.

    下载示例报告
  • nsclc profiler.

    揭示非小细胞肺癌患者的治疗方案(NSCLC)金博宝188亚洲体育app

    Our portfolio of tests analyzes genes and biomarkers for relevant alterations in patients with NSCLC, includingEGFR,alk.,ROS1,BRAF,NTRK, METex14, PD-L1和genomic signatures like TMB§.

    Download NSCLC Profiler
  • BLOG POST

    液体活检:来自一个不可能的想法,新的潜力出现了

    It’s always been an ambitious concept: By analyzing a patient’s blood, doctors might better understand their individual cancer, and thus better pinpoint what treatment options may be most effective. But yesterday’s ambition has become today’s reality—we’re living in an exciting time for this kind of test, known as liquid biopsy.

    READ FULL BLOG POST
  • PROSTATE PROFILER

    Unlocking New Treatment Options for Patients with Metastatic Prostate Cancer

    我们的投资组合的测试分析所有guideline-recommended genes and biomarkers for relevant alterations in patients with prostate cancer including:BRCA1,BRCA2,ATM,PALB2.,Fanca.,RAD51D,CHEK2,CDK12和MSI等基因组特征。*

    前列腺探查器

底座液体CDX资源

Need More Details?

Our client services team is here to help, Monday through Friday 8AM – 8PM EST.

联系我们

补充笔记

FoundationOne®Liquid CDx is FDA-approved to report substitutions and indels in 311 genes, including rearrangements inalk.BRCA1 / 2.并复制号码更改BRCA1 / 2.erbb2.(HER2)。跨所有324个基因的综合结果报告为实验室专业服务,该服务未被FDA审查或批准。

MSI status will be reported for samples determined to have high microsatellite instability as a laboratory professional service.

通过免疫组织化学(IHC)的PD-L1可以作为补充试验命令,可以为不同癌症类型的几种免疫治疗提供信息。

§FoundationOne Liquid CDx reports on bTMB as a laboratory professional service.

重要的安全信息

Select

FoundationOne Liquid CDx

Bodaine®Liquidcdx仅用于处方使用,是基于定性的下一代测序in vitrodiagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visitwww.f1lcdxlabel.com..